Treatment paradigms for patients with type 2 diabetes mellitus (DM) and heart failure (HF) has changed. Sodium glucose cotransporter 2 inhibitors, such as empagliflozin, are now considered potential first line therapies. Compliance to empagliflozin and the factors that may influence compliance are unknown. Methods: We assessed compliance and associated factors in patients with DM and HF from Veterans Affairs national data from 2015-22. Compliance was calculated using proportion of days covered (PDC). Compliance to empagliflozin was defined as PDC > 80%. Patients who compliance could not be calculated were excluded. Generalized linear models were constructed to evaluate 1) demographic, 2) patient level, and 3) system level data.

Results: Total 28,581 patients exposed to empagliflozin were included. Proportion of empagliflozin compliance was 66.2%. Table 1 displays the significant demographic, patient, and system level factors associated with poor empagliflozin compliance.

Conclusions: There were demographic, patient, and system level factors that were associated with poor empagliflozin compliance.


C.A.Alvarez: Research Support; Boehringer Ingelheim Inc. A.Perkins: None. M.A.Sigler: None. H.Yang: None. H.Caberwal: Employee; Boehringer Ingelheim Inc. R.Ebrahimi: Consultant; Pfizer Inc., Speaker's Bureau; Novo Nordisk.


Boehringer Ingelheim

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at